Evoke Pharma (EVOK)
(Delayed Data from NSDQ)
$0.45 USD
+0.01 (2.27%)
Updated Apr 30, 2024 03:57 PM ET
After-Market: $0.45 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EVOK 0.45 +0.01(2.27%)
Will EVOK be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for EVOK based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for EVOK
Evoke Pharma to hold a webinar
Evoke Pharma to hold a webinar
Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer
Evoke Pharma Welcomes Matthew D’Onofrio as New CEO